<?xml version="1.0" encoding="UTF-8"?>
<TEI xml:space="preserve" xmlns="http://www.tei-c.org/ns/1.0" 
xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" 
xsi:schemaLocation="http://www.tei-c.org/ns/1.0 https://raw.githubusercontent.com/kermitt2/grobid/master/grobid-home/schemas/xsd/Grobid.xsd"
 xmlns:xlink="http://www.w3.org/1999/xlink">
	<teiHeader xml:lang="en">
		<fileDesc>
			<titleStmt>
				<title level="a" type="main">Non-surgical management of knee osteoarthritis: where are we now and where do we need to go?</title>
			</titleStmt>
			<publicationStmt>
				<publisher/>
				<availability status="unknown"><licence/></availability>
				<date type="published" when="2015-02-18">18 February 2015</date>
			</publicationStmt>
			<sourceDesc>
				<biblStruct>
					<analytic>
						<author role="corresp">
							<persName><roleName>Professor</roleName><forename type="first">Frank</forename><surname>Buttgereit</surname></persName>
							<email>frank.buttgereit@charite.de</email>
							<affiliation key="aff1">
								<orgName type="department">Department of Rheumatology &amp; Clinical Immunology</orgName>
								<orgName type="institution">Charité University Medicine Berlin</orgName>
							</affiliation>
							<affiliation key="aff2">
								<orgName type="department">German Rheumatism Research Center (DRFZ) and Berlin-Brandenburg Center of Regenerative Therapies (BCRT)</orgName>
								<address>
									<settlement>Berlin</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Gerd-Rüdiger</forename><surname>Burmester</surname></persName>
							<affiliation key="aff1">
								<orgName type="department">Department of Rheumatology &amp; Clinical Immunology</orgName>
								<orgName type="institution">Charité University Medicine Berlin</orgName>
							</affiliation>
							<affiliation key="aff2">
								<orgName type="department">German Rheumatism Research Center (DRFZ) and Berlin-Brandenburg Center of Regenerative Therapies (BCRT)</orgName>
								<address>
									<settlement>Berlin</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Johannes</forename><forename type="middle">W J</forename><surname>Bijlsma</surname></persName>
							<affiliation key="aff3">
								<orgName type="department">Department of Rheumatology &amp; Clinical Immunology</orgName>
								<orgName type="institution">University Medical Center Utrecht</orgName>
								<address>
									<settlement>Utrecht</settlement>
									<country key="NL">The Netherlands</country>
								</address>
							</affiliation>
						</author>
						<author>
							<affiliation key="aff0">
								<orgName type="department">Buttgereit F</orgName>
								<orgName type="institution">Burmester G-R</orgName>
								<address>
									<settlement>Bijlsma JWJ</settlement>
								</address>
							</affiliation>
						</author>
						<title level="a" type="main">Non-surgical management of knee osteoarthritis: where are we now and where do we need to go?</title>
					</analytic>
					<monogr>
						<imprint>
							<date type="published" when="2015-02-18">18 February 2015</date>
						</imprint>
					</monogr>
					<idno type="MD5">C089BB6EBE59B5E958A8C99F78A23EC6</idno>
					<idno type="DOI">10.1136/rmdopen-2014-000027</idno>
					<note type="submission">Received 27 November 2014 Revised 4 December 2014 Accepted 12 December 2014</note>
				</biblStruct>
			</sourceDesc>
		</fileDesc>
		<encodingDesc>
			<appInfo>
				<application version="0.7.2-SNAPSHOT" ident="GROBID" when="2022-05-18T11:31+0000">
					<desc>GROBID - A machine learning software for extracting information from scholarly documents</desc>
					<ref target="https://github.com/kermitt2/grobid"/>
				</application>
			</appInfo>
		</encodingDesc>
		<profileDesc>
			<abstract/>
		</profileDesc>
	</teiHeader>
	<text xml:lang="en">
		<body>
<div xmlns="http://www.tei-c.org/ns/1.0"><p><s>After the successful treatment of inflammatory rheumatic diseases with targeted therapies, the greatest challenge in rheumatic diseases remains the treatment of the most common chronic joint disorder, osteoarthritis.</s><s>Osteoarthritis (OA) commonly affects the knee, with an age-standardised and sex-standardised incidence of 240 per 100.000</s><s>person-years.</s><s>With the aging of the population and rising obesity throughout the world, it is anticipated that the burden of OA will increase and become a major problem for health systems globally.</s><s>Given this background, proper guidance on the management of OA is needed.</s><s>This issue has been addressed over recent months in updated guidelines or recommendations detailing three treatment modalities: non-pharmacological, pharmacological and surgical.</s><s>It should be noted, that OA is not a uniform disease entity.</s><s>In some patients, progression of the disease seems to be driven by cartilage factors, in others by bone factors or by inflammatory factors.</s><s>Ongoing research aims to identify potential biomarkers for these different forms of OA.</s><s>Research is also underway into disease modifying OA drugs (DMOADs) that target different aspects of the disease, treatments for OA pain, and cell-based therapies.</s></p><p><s>After the successful treatment of inflammatory rheumatic diseases with targeted therapies, the greatest challenge in rheumatic diseases remains the treatment of the most common chronic joint disorder, osteoarthritis (OA).</s><s>OA is one of the most prevalent chronic diseases worldwide. <ref type="bibr" target="#b0">1</ref></s><s>Globally, hip and knee OA is ranked as the 11th highest contributor to global disability (measured by years lived with disability), and as the 38th highest in terms of overall burden (as measured by disability-adjusted life years) in 2010. <ref type="bibr" target="#b1">2</ref> With the aging of the population and rising obesity throughout the world, it is anticipated that the burden of OA will increase and become a major problem for health systems globally. <ref type="bibr" target="#b1">2</ref></s><s> commonly affects the knee, with an age-standardised and sex-standardised incidence of 240/100 000 person-years. <ref type="bibr" target="#b2">3</ref> Over the age of 80 years, more than half of women and one-third of men suffer from radiographical OA of the knee.</s><s><ref type="bibr" target="#b3">4</ref> The global prevalence of radiographically confirmed knee OA (Kellgren-Lawrence grades 2-4) was very recently estimated to be 3.8% (4.8% in females; 2.8% in males) with a peak at around 50 years of age. <ref type="bibr" target="#b1">2</ref> These data are in agreement with the earlier observation that females are at a higher risk of knee OA than men. <ref type="bibr" target="#b4">5</ref> A recently published cross-sectional analysis found that women also experience greater knee pain than men, regardless of Kellgren-Lawrence grade.</s><s><ref type="bibr" target="#b5">6</ref> Pain, inflammatory flares, stiffness and loss of movement and function represent major symptoms of OA including knee OA, resulting in a substantial adverse impact on patients' quality of life and considerable economic burden.</s><s><ref type="bibr">3 4 7</ref> Given this background, proper guidance on the management of OA is needed.</s><s>]<ref type="bibr" target="#b8">[9]</ref><ref type="bibr" target="#b9">[10]</ref><ref type="bibr" target="#b10">[11]</ref> In addition, the OA Research Society International (OARSI) guidelines for the nonsurgical management of knee OA were updated and published recently.</s><s>12 While previous OARSI guidelines addressed the management of hip and knee OA, the updated guidelines focused specifically on the knee, evaluating the safety and efficacy profiles of currently available treatment options.</s><s><ref type="bibr">12</ref> Given the relative paucity of novel data, the authors took an innovative approach to enhance the specificity of treatment recommendations: they defined OA clinical subphenotypes (knee-only OA with and without comorbidities; multijoint OA with and without comorbidities).</s></p><p><s>Commonly, we distinguish three treatment modalities: non-pharmacological, pharmacological and surgical. <ref type="bibr" target="#b3">4</ref></s><s>igure <ref type="figure">1</ref> summarises treatments OARSI recommends are 'Appropriate' in at least one of the four subphenotypes. <ref type="bibr">12</ref></s><s>ey suggest not using treatments rated 'Inappropriate' (eg, risedronate, electrotherapy), but others are rated 'Uncertain' (eg, acupuncture, chrondroitin, glucosamin or opioids).</s><s>For the latter, the authors recommend physician-patient interaction to determine whether this treatment may have merit for an individual patient.</s><s>Referral for consideration of orthopaedic surgical intervention is indicated after more conservative treatment options have been exhausted. <ref type="bibr">12</ref></s><s>Although both patients and doctors consider postponing surgery a success, for many patients joint replacement is eventually the final treatment option. <ref type="bibr" target="#b11">13</ref></s><s>his implies that, despite the variety of appropriate nonsurgical treatment options, there are still considerable limitations in either success rate or tolerability when treating established knee OA.</s></p><p><s>Excess weight and obesity are well-known risk factors for OA since they increase mechanical stress and induce systemic effects (eg,via adipokines and/or hyperglycaemia) involved in OA pathogenesis. <ref type="bibr" target="#b12">14</ref></s><s>It has been recently confirmed that in knee OA, mechanical stress is the most important underlying mechanism; this is in contrast to hand OA, where systemic processes appear to be most important. <ref type="bibr" target="#b12">14</ref></s><s>In line with this are results of a meta-analysis published in July 2014 indicating that knee OA risk increases almost exponentially according to the increase in body mass index (BMI). <ref type="bibr" target="#b13">15</ref></s><s>Furthermore, analysis of data available through the Osteoarthritis Initiative and the CHECK-cohort confirmed that individuals with higher BMI experience greater pain from Figure <ref type="figure">1</ref> Treatments considered 'Appropriate' in at least one of the four subphenotypes of knee osteoarthritis. 12</s><s>Quality of evidence is indicated by: bold=good; not bold=fair.</s><s>NSAIDs, non-steroidal anti-inflammatory drug.</s><s>* knee braces, knee sleeves, foot orthoses and lateral wedge insoles.</s></p><p><s>Table <ref type="table">1</ref> Studies investigating potential new non-surgical treatment options in knee OA (modified and updated from <ref type="bibr" target="#b19">21</ref> )</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Treatment option Studies Comments</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>DMOADs targeting cartilage</head><p><s>Intra-articular recombinant human fibroblast growth factor 18 (NCT01919164)</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Proanabolic growth factor</head><p><s>Intra-articular TPX-100 (NCT1925261) Chondrogenic peptide DMOADs targeting bone Oral strontium ranelate <ref type="bibr" target="#b23">[25]</ref><ref type="bibr" target="#b24">[26]</ref><ref type="bibr" target="#b25">[27]</ref> Remodelling of subchondral bone and articular cartilage DMOADs targeting synovitis</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Oral hydroxychloroqine and atorvastatin (NCT01645176)</head><p><s>A combination of a DMARD with a statin</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Oral methotrexate (NCT01654575)</head><p><s>A DMARD Oral SD-6010 (Cindunistat) <ref type="bibr" target="#b26">28</ref> Selective inhibitor of inducible nitric oxide synthase Subcutaneous ABT-981 (NCT01668511)</s></p><p><s>Monoclonal antihuman interleukin-1 α/β antibody Oral PRX167700 (NCT01945346)</s></p><p><s>Vascular adhesion protein-1 antagonist Treatments targeting pain Tanezumab <ref type="bibr" target="#b27">29</ref> Antinerve growth factor inhibitor CG100649 (NCT1765296)</s></p><p><s>Dual inhibitor of carbonic anhydrase and COX-2 AKR 202 (NCT02003118) Small molecule purinergic receptor modulator and enzyme inhibitor Cell-based therapies Allogenic mesenchymal stem cells (NCT01586312, NCT01985633, NCT01459640)</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Induction of interactive biological repair mechanisms involving stem cells Mesenchymal trophic factor (NCT02003131) Autologous adipose derived stem cells (NCT01585857)</head><p><s>The NCT identification number refers to trials registered in ClinicalTrials.gov</s><s>(http://clinicaltrials.gov) where more in detail information can be obtained.</s><s>DMOAD, disease-modifying antiosteoarthritic drug; DMARD, disease-modifying antirheumatic drug; OA, osteoarthritis.</s></p><p><s>knee OA than individuals with lower BMI, even when taking into account OA severity. <ref type="bibr">16 17</ref></s><s>Therefore, successful management of knee OA includes reduction of adverse mechanical factors (ie, weight loss in patients who are overweight or obese). <ref type="bibr" target="#b10">11</ref></s><s>Exercise is also beneficial, as shown in a recently published randomised controlled trial in women with OA of the knee. <ref type="bibr" target="#b16">18</ref></s><s>rogressive resistance exercise reduced pain, improved function, increased strength and showed benefits on some quality of life domains. <ref type="bibr" target="#b16">18</ref></s><s>However, apart from these approaches and education about the disease, there is little to offer patients for prevention or early treatment that is directed at the cause of the disease. <ref type="bibr" target="#b17">19</ref></s><s>hy have researchers failed so far to develop effective and safe disease modifying OA drugs (DMOADs) for the millions of patients suffering from this serious and disabling disease?</s><s>One major reason is that pathogenesis of this disease is not fully understood. <ref type="bibr" target="#b11">13</ref></s><s>OA is considered to result from failure of the repair of damaged cartilage. <ref type="bibr" target="#b3">4</ref></s><s>However, recent evidence shows an additional and integrated role of bone and synovial tissue, at least in some patients with OA. <ref type="bibr" target="#b18">20</ref> Clearly, OA is not a uniform disease entity.</s><s>In some patients, progression of the disease seems to be driven by cartilage factors, in others by bone factors or by inflammatory factors. <ref type="bibr">4 21</ref></s><s>Ongoing research aims to identify potential biomarkers for cartilage-driven, bone-driven and synovitis-driven forms of OA.</s><s>In a very recent intriguing study, Beyer et al <ref type="bibr" target="#b20">22</ref> identified differentially expressed miRNAs as predictors for severe knee and hip OA.</s><s>This is an important observation since circulating miRNAs are easily accessible and stable.</s><s>Only a few biomarkers that reflect bone and cartilage metabolism have shown value in predicting OA, <ref type="bibr" target="#b21">23</ref> and none has so far entered routine clinical practice.</s><s>Therefore, specific miRNAs, such as let-7e, may prove useful biomarkers for OA. <ref type="bibr" target="#b20">22</ref></s><s>esearch is also underway into DMOADs that target different aspects of the disease, treatments for OA pain and cell-based therapies; table 1 lists studies in these areas that we consider promising.</s><s>Apart from these novel non-surgical approaches, a new surgical method is also in development-intrinsic cartilage repair by joint distraction. <ref type="bibr" target="#b19">21</ref></s><s>espite these widespread and promising current research activities, many questions about OA and its treatment still require answers (box 1).</s><s>The EU has recognised rheumatic and musculoskeletal diseases as 'major diseases', which may trigger research.</s><s>Priorities in OA research include predictors of progression, understanding mechanisms of pain and tissue communication, developing concepts and interventions for early OA and the need for new treatment strategies. <ref type="bibr" target="#b22">24</ref></s><s>This research agenda represents useful guidance for researchers in the field.</s><s>We believe that putting as much effort into OA research as was seen in recent years in RA research may yield significant progress in improving quality of life for many patients with OA.</s><s>Real possibilities are visible on the horizon.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Competing interests None.</head><p><s>Provenance and peer review Not commissioned; externally peer reviewed.</s></p><p><s>Data sharing statement No additional data are available.</s></p><p><s>Open Access This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work noncommercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial.</s><s>See: http:// creativecommons.org/licenses/by-nc/4.0/</s></p></div>			<note xmlns="http://www.tei-c.org/ns/1.0" place="foot">on May 17, 2022 by guest. Protected by copyright. http://rmdopen.bmj.com/ RMD Open: first published as 10.1136/rmdopen-2014-000027 on 18 February 2015. Downloaded from</note>
		</body>
		<back>
			<div type="annex">
<div xmlns="http://www.tei-c.org/ns/1.0"><p><s>Box 1 Challenges in the treatment of OA ▸ When does OA start and how can we define this time point?</s><s>▸ Which programmes are most effective to educate patients about the benefits of current preventive measures (such as weight loss and exercise)?</s><s>▸ If a novel DMOAD is discovered how can we select patients who will benefit most (different phenotypes, different points of action)?</s><s>▸ If a novel DMOAD is discovered that needs to be administered before pronounced symptoms develop, will patients adhere to treatment when other preventive measures (such as weight loss and exercise) are currently poorly followed?</s><s>▸ When should surgery be recommended?</s><s>At an early time point when quality of life is still good or at a later time because of economic restraints and the limited life span of endoprosthetic material?</s><s>▸ When will regenerative medicine (including tissue engineering) result in materials to repair damaged joints that provide an alternative to the metal and ceramics currently used?</s></p></div>			</div>
			<div type="references">

				<listBibl>

<biblStruct xml:id="b0">
	<analytic>
		<title/>
		<author>
			<persName><forename type="first">L</forename><surname>Busija</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Bridgett</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">R</forename><surname>Williams</surname></persName>
		</author>
		<idno type="DOI">10.1016/j.berh.2010.11.001</idno>
	</analytic>
	<monogr>
		<title level="j">Best Pract Res Clin Rheumatol</title>
		<imprint>
			<biblScope unit="volume">24</biblScope>
			<biblScope unit="page" from="757" to="768" />
			<date type="published" when="2010">2010</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b1">
	<analytic>
		<title level="a" type="main">The global burden of hip and knee osteoarthritis: estimates from the Global Burden of Disease 2010 study</title>
		<author>
			<persName><forename type="first">M</forename><surname>Cross</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Smith</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Hoy</surname></persName>
		</author>
		<idno type="DOI">10.1136/annrheumdis-2013-204763</idno>
	</analytic>
	<monogr>
		<title level="j">Ann Rheum Dis</title>
		<imprint>
			<biblScope unit="volume">73</biblScope>
			<biblScope unit="page" from="1323" to="1330" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b2">
	<analytic>
		<title level="a" type="main">Incidence of symptomatic hand, hip, and knee osteoarthritis among patients in a health maintenance organization</title>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">A</forename><surname>Oliveria</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">T</forename><surname>Felson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">I</forename><surname>Reed</surname></persName>
		</author>
		<idno type="DOI">10.1002/art.1780380817</idno>
	</analytic>
	<monogr>
		<title level="j">Arthritis Rheum</title>
		<imprint>
			<biblScope unit="volume">38</biblScope>
			<biblScope unit="page" from="1134" to="1141" />
			<date type="published" when="1995">1995</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b3">
	<analytic>
		<title level="a" type="main">Osteoarthritis: an update with relevance for clinical practice</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">W</forename><surname>Bijlsma</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Berenbaum</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><forename type="middle">P</forename><surname>Lafeber</surname></persName>
		</author>
		<idno type="DOI">10.1016/S0140-6736(11)60243-2</idno>
	</analytic>
	<monogr>
		<title level="j">Lancet</title>
		<imprint>
			<biblScope unit="volume">377</biblScope>
			<biblScope unit="page" from="2115" to="2126" />
			<date type="published" when="2011">2011</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b4">
	<analytic>
		<title level="a" type="main">A meta-analysis of sex differences prevalence, incidence and severity of osteoarthritis</title>
		<author>
			<persName><forename type="first">V</forename><forename type="middle">K</forename><surname>Srikanth</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">L</forename><surname>Fryer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Zhai</surname></persName>
		</author>
		<idno type="DOI">10.1016/j.joca.2005.04.014</idno>
	</analytic>
	<monogr>
		<title level="j">Osteoarthritis Cartilage</title>
		<imprint>
			<biblScope unit="volume">13</biblScope>
			<biblScope unit="page" from="769" to="781" />
			<date type="published" when="2005">2005</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b5">
	<analytic>
		<title level="a" type="main">Examining sex differences in knee pain: the Multicenter Osteoarthritis Study</title>
		<author>
			<persName><forename type="first">N</forename><surname>Glass</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><forename type="middle">A</forename><surname>Segal</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">A</forename><surname>Sluka</surname></persName>
		</author>
		<idno type="DOI">10.1016/j.joca.2014.06.030</idno>
	</analytic>
	<monogr>
		<title level="j">Osteoarthritis Cartilage</title>
		<imprint>
			<biblScope unit="volume">22</biblScope>
			<biblScope unit="page" from="1100" to="1106" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b6">
	<analytic>
		<title level="a" type="main">Osteoarthritis: quality of life, comorbidities, medication and health service utilization assessed in a large sample of primary care patients</title>
		<author>
			<persName><forename type="first">T</forename><surname>Rosemann</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Laux</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Szecsenyi</surname></persName>
		</author>
		<idno type="DOI">10.1186/1749-799X-2-12</idno>
	</analytic>
	<monogr>
		<title level="j">J Orthop Surg Res</title>
		<imprint>
			<biblScope unit="volume">2</biblScope>
			<biblScope unit="page">12</biblScope>
			<date type="published" when="2007">2007</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b7">
	<analytic>
		<title level="a" type="main">The American Academy of Orthopaedic Surgeons evidence-based guideline on: treatment of osteoarthritis of the knee</title>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">S</forename><surname>Jevsevar</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><forename type="middle">A</forename><surname>Brown</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">L</forename><surname>Jones</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Bone Joint Surg Am</title>
		<imprint>
			<biblScope unit="volume">95</biblScope>
			<biblScope unit="page" from="1885" to="1886" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
	<note>2nd edition</note>
</biblStruct>

<biblStruct xml:id="b8">
	<analytic>
		<title level="a" type="main">American College of Rheumatology 2012 recommendations for the use of nonpharmacologic and pharmacologic therapies in osteoarthritis of the hand, hip, and knee</title>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">C</forename><surname>Hochberg</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">D</forename><surname>Altman</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">T</forename><surname>April</surname></persName>
		</author>
		<idno type="DOI">10.1002/acr.21596</idno>
	</analytic>
	<monogr>
		<title level="j">Arthritis Care Res</title>
		<imprint>
			<biblScope unit="volume">64</biblScope>
			<biblScope unit="page" from="465" to="474" />
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b9">
	<analytic>
		<title level="a" type="main">EULAR recommendations for the non-pharmacological core management of hip and knee osteoarthritis</title>
		<author>
			<persName><forename type="first">L</forename><surname>Fernandes</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">B</forename><surname>Hagen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">W</forename><surname>Bijlsma</surname></persName>
		</author>
		<idno type="DOI">10.1136/annrheumdis-2012-202745</idno>
	</analytic>
	<monogr>
		<title level="j">Ann Rheum Dis</title>
		<imprint>
			<biblScope unit="volume">72</biblScope>
			<biblScope unit="page" from="1125" to="1135" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b10">
	<analytic>
		<title level="a" type="main">An algorithm recommendation for the management of knee osteoarthritis in Europe and internationally: a report from a task force of the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO)</title>
		<author>
			<persName><forename type="first">O</forename><surname>Bruyere</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Cooper</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">P</forename><surname>Pelletier</surname></persName>
		</author>
		<idno type="DOI">10.1016/j.joca.2014.01.003</idno>
		<ptr target="http://rmdopen.bmj.com/RMDOpen" />
	</analytic>
	<monogr>
		<title level="m">Osteoarthritis on May 17, 2022 by guest. Protected by copyright</title>
				<imprint>
			<date type="published" when="2014-02">2014. February 2015. 2014</date>
			<biblScope unit="volume">44</biblScope>
			<biblScope unit="page" from="363" to="388" />
		</imprint>
	</monogr>
	<note>Semin Arthritis Rheum</note>
</biblStruct>

<biblStruct xml:id="b11">
	<analytic>
		<title level="a" type="main">The disease modifying osteoarthritis drug (DMOAD): is it in the horizon?</title>
		<author>
			<persName><forename type="first">P</forename><surname>Qvist</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">C</forename><surname>Bay-Jensen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Christiansen</surname></persName>
		</author>
		<idno type="DOI">10.1016/j.phrs.2008.06.001</idno>
	</analytic>
	<monogr>
		<title level="j">Pharmacol Res</title>
		<imprint>
			<biblScope unit="volume">58</biblScope>
			<biblScope unit="page" from="1" to="7" />
			<date type="published" when="2008">2008</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b12">
	<analytic>
		<title level="a" type="main">The relative contribution of mechanical stress and systemic processes in different types of osteoarthritis: the NEO study</title>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">W</forename><surname>Visser</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>De Mutsert</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Le Cessie</surname></persName>
		</author>
		<idno type="DOI">10.1136/annrheumdis-2013-205012</idno>
	</analytic>
	<monogr>
		<title level="j">Ann Rheum Dis</title>
		<imprint>
			<date type="published" when="2014-05-20">2014. 20 May 2014</date>
		</imprint>
	</monogr>
	<note>Published Online First</note>
</biblStruct>

<biblStruct xml:id="b13">
	<analytic>
		<title level="a" type="main">Body mass index and knee osteoarthritis risk: a dose-response meta-analysis</title>
		<author>
			<persName><forename type="first">Z</forename><forename type="middle">Y</forename><surname>Zhou</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><forename type="middle">K</forename><surname>Liu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">L</forename><surname>Chen</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Obesity</title>
		<imprint>
			<biblScope unit="volume">22</biblScope>
			<biblScope unit="page" from="2180" to="2185" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b14">
	<analytic>
		<title level="a" type="main">Knee osteoarthritis, body mass index and pain: data from the Osteoarthritis Initiative</title>
		<author>
			<persName><forename type="first">E</forename><surname>Weiss</surname></persName>
		</author>
		<idno type="DOI">10.1093/rheumatology/keu244</idno>
	</analytic>
	<monogr>
		<title level="j">Rheumatology</title>
		<imprint>
			<biblScope unit="volume">53</biblScope>
			<biblScope unit="page" from="2095" to="2099" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b15">
	<analytic>
		<title level="a" type="main">Worsening of pain and function over 5 years in individuals with &apos;early&apos; OA is related to structural damage: data from the Osteoarthritis Initiative and CHECK (Cohort Hip &amp; Cohort Knee) study</title>
		<author>
			<persName><forename type="first">J</forename><surname>Wesseling</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">M</forename><surname>Bierma-Zeinstra</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Kloppenburg</surname></persName>
		</author>
		<idno type="DOI">10.1136/annrheumdis-2013-203829</idno>
	</analytic>
	<monogr>
		<title level="j">Ann Rheum Dis</title>
		<imprint>
			<date type="published" when="2013-11">2013. Nov 2013</date>
		</imprint>
	</monogr>
	<note>Published Online First: 15</note>
</biblStruct>

<biblStruct xml:id="b16">
	<analytic>
		<title level="a" type="main">Progressive resistance exercise in women with osteoarthritis of the knee: a randomized controlled trial</title>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">T</forename><surname>Jorge</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">C</forename><surname>Souza</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Chiari</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Clin Rehabil</title>
		<imprint>
			<date type="published" when="2014-07">2014. Jul 2014</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b17">
	<analytic>
		<title/>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">B</forename><surname>Goldring</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">R</forename><surname>Goldring</surname></persName>
		</author>
		<author>
			<persName><surname>Osteoarthritis</surname></persName>
		</author>
		<idno type="DOI">10.1002/jcp.21258</idno>
	</analytic>
	<monogr>
		<title level="j">J Cell Physiol</title>
		<imprint>
			<biblScope unit="volume">213</biblScope>
			<biblScope unit="page" from="626" to="634" />
			<date type="published" when="2007">2007</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b18">
	<analytic>
		<title level="a" type="main">The role of synovitis in pathophysiology and clinical symptoms of osteoarthritis</title>
		<author>
			<persName><forename type="first">J</forename><surname>Sellam</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Berenbaum</surname></persName>
		</author>
		<idno type="DOI">10.1038/nrrheum.2010.159</idno>
	</analytic>
	<monogr>
		<title level="j">Nat Rev Rheumatol</title>
		<imprint>
			<biblScope unit="volume">6</biblScope>
			<biblScope unit="page" from="625" to="635" />
			<date type="published" when="2010">2010</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b19">
	<analytic>
		<title level="a" type="main">Functional articular cartilage repair: here, near, or is the best approach not yet clear?</title>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">C</forename><surname>Mastbergen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">B</forename><surname>Saris</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><forename type="middle">P</forename><surname>Lafeber</surname></persName>
		</author>
		<idno type="DOI">10.1038/nrrheum.2013.29</idno>
	</analytic>
	<monogr>
		<title level="j">Nat Rev Rheumatol</title>
		<imprint>
			<biblScope unit="volume">9</biblScope>
			<biblScope unit="page" from="277" to="290" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b20">
	<analytic>
		<title level="a" type="main">Signature of circulating microRNAs in osteoarthritis</title>
		<author>
			<persName><forename type="first">C</forename><surname>Beyer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Zampetaki</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><forename type="middle">Y</forename><surname>Lin</surname></persName>
		</author>
		<idno type="DOI">10.1136/annrheumdis-2013-204698</idno>
	</analytic>
	<monogr>
		<title level="j">Ann Rheum Dis</title>
		<imprint>
			<date type="published" when="2014-02-27">2014. 27 Feb 2014</date>
		</imprint>
	</monogr>
	<note>Published Online First</note>
</biblStruct>

<biblStruct xml:id="b21">
	<analytic>
		<title level="a" type="main">Vascular cell adhesion molecule 1 as a predictor of severe osteoarthritis of the hip and knee joints</title>
		<author>
			<persName><forename type="first">G</forename><surname>Schett</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Kiechl</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Bonora</surname></persName>
		</author>
		<idno type="DOI">10.1002/art.24757</idno>
	</analytic>
	<monogr>
		<title level="j">Arthritis Rheum</title>
		<imprint>
			<biblScope unit="volume">60</biblScope>
			<biblScope unit="page" from="2381" to="2389" />
			<date type="published" when="2009">2009</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b22">
	<analytic>
		<title level="a" type="main">Osteoarthritis research priorities: a report from a EULAR ad hoc expert committee</title>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">G</forename><surname>Conaghan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Kloppenburg</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Schett</surname></persName>
		</author>
		<idno type="DOI">10.1136/annrheumdis-2013-204660</idno>
	</analytic>
	<monogr>
		<title level="j">Ann Rheum Dis</title>
		<imprint>
			<biblScope unit="volume">73</biblScope>
			<biblScope unit="page" from="1442" to="1445" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b23">
	<analytic>
		<title level="a" type="main">Efficacy and safety of strontium ranelate in the treatment of knee osteoarthritis: results of a double-blind, randomised placebo-controlled trial</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">Y</forename><surname>Reginster</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Badurski</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><surname>Bellamy</surname></persName>
		</author>
		<idno type="DOI">10.1136/annrheumdis-2012-202231</idno>
	</analytic>
	<monogr>
		<title level="j">Ann Rheum Dis</title>
		<imprint>
			<biblScope unit="volume">72</biblScope>
			<biblScope unit="page" from="179" to="186" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b24">
	<analytic>
		<title level="a" type="main">Disease-modifying effect of strontium ranelate in a subset of patients from the Phase III knee osteoarthritis study SEKOIA using quantitative MRI: reduction in bone marrow lesions protects against cartilage loss</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">P</forename><surname>Pelletier</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Roubille</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">P</forename><surname>Raynauld</surname></persName>
		</author>
		<idno type="DOI">10.1136/annrheumdis-2013-203989</idno>
	</analytic>
	<monogr>
		<title level="j">Ann Rheum Dis</title>
		<imprint>
			<date type="published" when="2013-12-02">2013. 2 Dec 2013</date>
		</imprint>
	</monogr>
	<note>Published Online First</note>
</biblStruct>

<biblStruct xml:id="b25">
	<analytic>
		<title level="a" type="main">Clinically meaningful effect of strontium ranelate on symptoms in knee osteoarthritis: a responder analysis</title>
		<author>
			<persName><forename type="first">O</forename><surname>Bruyere</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">Y</forename><surname>Reginster</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><surname>Bellamy</surname></persName>
		</author>
		<idno type="DOI">10.1093/rheumatology/keu018</idno>
	</analytic>
	<monogr>
		<title level="j">Rheumatology</title>
		<imprint>
			<biblScope unit="volume">53</biblScope>
			<biblScope unit="page" from="1457" to="1464" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b26">
	<analytic>
		<title level="a" type="main">A 2-year randomised, double-blind, placebo-controlled, multicentre study of oral selective iNOS inhibitor, cindunistat (SD-6010), in patients with symptomatic osteoarthritis of the knee</title>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">P</forename><surname>Hellio Le Graverand</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">S</forename><surname>Clemmer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Redifer</surname></persName>
		</author>
		<idno type="DOI">10.1136/annrheumdis-2012-202239</idno>
	</analytic>
	<monogr>
		<title level="j">Ann Rheum Dis</title>
		<imprint>
			<biblScope unit="volume">72</biblScope>
			<biblScope unit="page" from="187" to="195" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b27">
	<analytic>
		<title level="a" type="main">Efficacy and safety of tanezumab monotherapy or combined with non-steroidal anti-inflammatory drugs in the treatment of knee or hip osteoarthritis pain</title>
		<author>
			<persName><forename type="first">T</forename><forename type="middle">J</forename><surname>Schnitzer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">F</forename><surname>Ekman</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">L</forename><surname>Spierings</surname></persName>
		</author>
		<idno type="DOI">10.1136/annrheumdis-2013-204905</idno>
	</analytic>
	<monogr>
		<title level="j">Ann Rheum Dis</title>
		<imprint>
			<biblScope unit="issue">13</biblScope>
			<date type="published" when="2014-03">2014. Mar 2014</date>
		</imprint>
	</monogr>
	<note>Published Online First</note>
</biblStruct>

				</listBibl>
			</div>
		</back>
	</text>
</TEI>
